Diabetes-Specific Oral Nutritional Supplements Improve Postprandial Glycemic Response in Prediabetes

Your standard oral nutritional supplement (ONS) is a problem for prediabetic patients. It spikes blood glucose. That spike is exactly what they don't need. A recent study tested a diabetes-specific formula, and the numbers are striking.

This isn't about tiny tweaks. The difference in postprandial glucose response was massive. If you build or buy ONS products, read this carefully.

Background

Prediabetes affects over 700 million adults globally. These patients often rely on ONS for medical nutrition therapy. Yet most standard formulas are carbohydrate-heavy. They deliver fast-digesting sugars that worsen glycemic control. A diabetes-specific nutritional formula (DSNF) aims to fix that. This study put one to the test.

Allulose played a central role. The DSNF contained 3g of allulose per 200mL. The standard ONS had zero. Allulose is a rare sugar with a clean sweet taste. It also has a unique metabolic profile. It isn't metabolized like regular sugar, and research suggests it actively helps regulate glucose.

What the Study Did

The research, published in Nutrition Research and Practice (DOI: 10.4162/nrp.2025.19.6.904), compared two oral supplements. One was a diabetes-specific formula. The other was a standard ONS. Both were given to subjects with prediabetes.

The researchers measured postprandial glucose responses. Specifically, they calculated the incremental area under the curve (iAUC). This captures the total glucose exposure after drinking the supplement. The DSNF wasn't just "a bit better." It outperformed the standard formula by a wide margin.

The DSNF also had lower available carbohydrates than the standard ONS. That likely contributed to the effect, but allulose wasn't just filler. The authors pointed to three specific mechanisms. Allulose inhibits glucose absorption in the gut. It stimulates GLP-1 release, which boosts insulin secretion. And it promotes glycogen storage in the liver. Each action dampens the post-meal glucose surge.

Key Findings

The headline number is the iAUC comparison. Here's the data:

Parameter	DSNF (with 3g allulose)	Standard ONS	Significance
Postprandial glucose iAUC	1,683.49	4,455.92	P < 0.0001

That's a 62% reduction in postprandial glucose response. Think about what that means for a patient's daily glucose variability. A single serving of standard ONS produces a glucose curve nearly three times higher than the diabetes-specific formula. For formulators, this is a strong signal.

Allulose appears to do the heavy lifting. The study's discussion cited its glucose-regulating actions, not just its lower sweetness or bulk properties. This isn't a sweetener substitution. It's a functional ingredient with measurable physiological effects.

What This Means for Formulators

You have two levers to pull. The first is carbohydrate reduction. Cut the available carbs in your ONS. The second is adding allulose at a meaningful dose. Three grams per 200mL worked here. That's a practical amount for a single-serve bottle.

Taste matters too. Allulose is about 70% as sweet as sucrose. It has a clean, sugar-like profile with no cooling aftertaste. That makes it a good fit for ONS products, where patient compliance depends on palatability. You can also pair it with high-intensity sweeteners to hit target sweetness without extra carbs.

For ingredient buyers, allulose supply has expanded in recent years. It's available in bulk quantities as a syrup or crystalline powder. It's stable under heat and low pH, which simplifies processing. And it has GRAS status in the US and similar approvals in other regions.

Labeling is another angle. You can highlight "diabetes-specific" or "low glycemic response" if your evidence supports it. This study gives you clinical data to back such claims. Just be careful with regulatory language in your target markets.

One caveat: this was a single study with a specific formula. You can't guarantee identical results with your own blend. But the mechanism is sound and the effect size is large. That's enough to justify pilot trials on your own products.

FAQ

Is 3g of allulose per serving enough to see real benefits?
In this study, yes. The DSNF contained 3g per 200mL and produced a significantly lower iAUC than the standard formula. The effect was substantial, so this dose appears clinically meaningful.

Does allulose affect the glycemic index of a product?
Allulose itself has a negligible glycemic response. It also appears to reduce the response to co-ingested carbohydrates. That's why the DSNF's iAUC was so much lower than the standard ONS.

Will allulose require label changes?
It depends on your market. In the US, allulose is excluded from total sugar and added sugar counts on Nutrition Facts labels, though it's listed separately. You'll need to review the regulations for each country you sell to.

Closing

This trial gives you a concrete target. A diabetes-specific ONS with 3g of allulose and lower available carbs can slash postprandial glucose iAUC by nearly two-thirds. Standard formulas don't cut it for this patient population. The evidence is clean, the mechanism is logical, and the ingredient is available now. That's a combination you rarely see in clinical nutrition. Act on it while your competitors are still reading abstracts.